investment which depending on government policies, direction of Baht currency and delay of 2020 government budget approval. Also, Coronavirus outbreak and the droughts in Thailand have been affecting to the

money received from the IPO after deducting the actual expenses 4. Acquisition of all ordinary shares of Modern Pharma Company Limited, "Modern Company", which is a transaction concerning asset

issuer has been in operation), in the same currency as the financial statements provided in response to Part VIII. Financial Information. If interim period financial statements are included, the selected

be presented for the three most recent financial years (or such shorter period that the issuer has been in operation), in the same currency as the financial statements provided in response to Part VIII

by depreciation of Thai Baht. Gain on foreign currency exchange was mainly associated with the USD loan related to the SGAH transaction and was non-cash in nature. Net profit (loss) attributable to

1,359 MB increased from 9M/2016 which was at 885 MB. However, the company’s performance was still impacted from Stock Loss and appreciating Baht currency which resulted in the reported net profit in

pay1 provision in 2Q19 and employee remuneration in 4Q19. Net FX gain was Bt308mn, increasing from Bt119mn in FY18, which was mostly unrealized gain from fluctuated currency whereas foreign debts were

- commissioning activities planned in December 2017 and startup early 2018. In addition to improved cash flows as a result of the better performance, the Company’s Balance Sheet al- so strengthened as a consequence

]) Factsheet Type of structure notes:  long-term structured notes Tenor:  short-term structured notes Issue date: Currency: Maturity date: Credit rating:1  None  Guarantor/Aval  Issue  Issuer Rated by on

Resources CONTENTS Executive Summary and Management Guidelines to Mitigate the Effects of the COVID-19 Outbreak 03 Statement of Income 09 Business Performance 11 Statement of Financial Position 24 Cash of